Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update
Globe Newswire•10/11/2026•16:02 ET
0
Key Highlights
- ➤KOMZIFTI revenue $13.9 million, up 53% sequentially in 3Q 2026
- ➤KOMZIFTI new patient starts increased 30% to approximately 150
- ➤Kura secured up to $300 million in potential Oberland financing
- ➤FDA aligned on approximately 40-patient darlifarnib salivary gland study
- ➤Kura cut 2026 collaboration revenue guidance to $40 million-$45 million
Expert Statements
Troy Wilson, President and Chief Executive Officer of Kura Oncology
“KOMZIFTI delivered strong commercial performance this quarter, with 53% sequential revenue growth, a 30% increase in new patients starts, and continued majority share of new patient starts”
Troy Wilson, President and Chief Executive Officer of Kura Oncology
“We believe these results demonstrate the growing commercial potential of KOMZIFTI and provide a strong foundation as we advance ziftomenib into the substantially larger frontline AML opportunity.”
Troy Wilson, President and Chief Executive Officer of Kura Oncology
“We have also reached FDA alignment on our planned registrational study of darlifarnib in HRAS-mutant salivary gland cancer, providing a potential path to our second product approval as we continue to pursue broader opportunities with combinations in solid tumors.”
Troy Wilson, President and Chief Executive Officer of Kura Oncology
“With a strengthened financial position, we believe we are well positioned to execute on these priorities and build two differentiated precision oncology franchises.”
– KOMZIFTI(®) (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% –
– KOMZIFTI maintained majority share of new patient starts of the menin inhibitor class in the R/R NPM1-mutated AML market –
Get started
Create a free account to read the full story.